IP Library Granted Patent US 10,201,598
Granted Patent B2
US 10,201,598 · App. 15/715,300 · Granted Feb 12, 2019

Synthetic immunogens for prophylaxis or treatment of tuberculosis

Inventors: David B. Weiner (Merion, PA); Daniel Villarreal (San Diego, CA)
Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
A61K39/04A61K39/07A61K45/06A61K2039/53
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,201,598
App. No.
15/715,300
Granted
Feb 12, 2019
Kind
B2
Abstract

Compositions comprising a nucleic acid molecule that encodes TB esat-6 proteins are disclosed. Methods of inducing an immune response against TB an individual are disclosed. Method of treating an individual who has been diagnosed with TB are disclosed. Method of preventing TB infection in an individual are disclosed.

Claims (12)

1. A composition comprising one or more polypeptides selected from the group consisting of:

a) one or more polypeptide molecules selected from the group consisting of: a polypeptide comprising the combination of esxV, esxS and esxW, a polypeptide comprising the combination of esxD, esxQ and esxE, a polypeptide comprising the combination of esxH, esxA and esxT, a polypeptide comprising the combination of esxB, esxC and esxU, a polypeptide comprising the combination of esxO, esxR and esxF, a polypeptide comprising the combination of at least three esxA, a polypeptide comprising the combination of Ag85A and esxA, a polypeptide comprising the combination of Ag85B and esxA, and a polypeptide comprising the combination of esxH, esxA, esxU, esxS, esxD, and esxV; and

b) a polypeptide comprising one or more sequences selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:28, fragments thereof having at least 90% of full length, homologous sequences having at least 95% homology, and fragments of homologous sequences having at least 95% homology, said fragment of homologous sequences having at least 95% homology having at least 90% of full length.

2. The composition of claim 1 comprising a combination of a polypeptide comprising SEQ ID NO:20, a polypeptide comprising SEQ ID NO:22, a polypeptide comprising SEQ ID NO:24, a polypeptide comprising SEQ ID NO:26, and a polypeptide comprising SEQ ID NO:28.

3. The composition of claim 1 comprising a combination of a polypeptide comprising esxV, esxS and esxW, a polypeptide comprising esxD, esxQ and esxE, a polypeptide comprising esxH, esxA and esxT, a polypeptide comprising esxB, esxC and esxU, and a polypeptide comprising esxO, esxR and esxF.

4. The composition of claim 3 comprising a combination of a polypeptide comprising SEQ ID NO:20 or SEQ ID NO:2, a polypeptide comprising SEQ ID NO:22 or SEQ ID NO:4, a polypeptide comprising SEQ ID NO:24 or SEQ ID NO:6, a polypeptide comprising SEQ ID NO:26 or SEQ ID NO:8, and a polypeptide comprising SEQ ID NO:28 or SEQ ID NO:10.

5. The composition of claim 1 comprising a polypeptide selected from the group consisting of: SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, and SEQ ID NO:28.

6. The composition of claim 1 comprising: a polypeptide comprising SEQ ID NO:2, a polypeptide comprising SEQ ID NO:4, a polypeptide comprising SEQ ID NO:6, a polypeptide comprising SEQ ID NO:8, and a polypeptide comprising SEQ ID NO:10.

7. The composition of claim 1 further comprising one or more proteins selected from the group consisting of: IL-12, IL-15 and IL-28.

8. The composition of claim 1 formulated for delivery to an individual using electroporation.

9. A method of inducing an immune response against TB comprising administering the composition of claim 1 to an individual in an amount effective to induce an immune response in said individual.

10. A method of treating an individual who has been diagnosed with TB comprising administering a therapeutically effective amount of the composition of claim 1 to an individual.

Continuity (3)
Division 14774399
Provisional Application 61800375 · Mar 15, 2013
Related Publication 20180078631A1 · Mar 22, 2018